EUFOREA consensus on biologics for CRSwNP with or without asthma

被引：270

作者：

Fokkens, Wytske J. ^{[1
,2
]}

Lund, Valerie ^{[3
]}

Bachert, Claus ^{[2
,4
,5
,6
]}

Mullol, Joaquim ^{[7
]}

Bjermer, Leif ^{[8
]}

Bousquet, Jean ^{[2
,9
]}

Canonica, Giorgio W. ^{[10
,11
]}

Deneyer, Lauren ^{[2
]}

Desrosiers, Martin ^{[12
]}

Diamant, Zuzana ^{[8
,13
,14
,15
,16
,17
]}

Han, Joseph ^{[18
]}

Heffler, Enrico ^{[10
,11
]}

Hopkins, Claire ^{[19
]}

Jankowski, Roger ^{[20
]}

Joos, Guy ^{[21
]}

Knill, Andrew ^{[22
]}

Lee, Jivianne ^{[23
]}

Lee, Stella E. ^{[24
]}

Marien, Gert ^{[2
]}

Pugin, Benoit ^{[2
,25
]}

Senior, Brent ^{[26
]}

Seys, Sven F. ^{[2
,25
]}

Hellings, Peter W. ^{[1
,2
,25
,27
]}

机构：

[1] Amsterdam Univ Med Ctr, Dept Otorhinolaryngol, Locat AMC Amsterdam, Amsterdam, Netherlands

[2] European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium

[3] Univ Coll London Hosp, Royal Natl Throat Nose & Ear Hosp, London, England

[4] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium

[5] Karolinska Univ Hosp, Karolinska Inst, CLINTEC, Div ENT Dis, Stockholm, Sweden

[6] Karolinska Univ Hosp, Dept ENT Dis, Stockholm, Sweden

[7] Univ Barcelona, Hosp Clin, Dept Otorhinolaryngol, CIBERES,IDIBAPS, Barcelona, Catalonia, Spain

[8] Lund Univ, Dept Resp Med & Allergol, Lund, Sweden

[9] Univ Hosp Arnaud de Villeneuve, Dept Resp Dis, Montpellier, France

[10] IRCCS, Personalized Med Asthma & Allergy Humanitas Clin, Rozzano, MI, Italy

[11] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, MI, Italy

[12] Univ Montreal Hosp Ctr CHUM, Div Otolaryngol Head & Neck Surg, Montreal, PQ, Canada

[13] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands

[14] Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands

[15] QPS NL, Groningen, Netherlands

[16] Charles Univ Prague, Fac Med 1, Dept Resp Med, Prague, Czech Republic

[17] Thomayer Hosp, Prague, Czech Republic

[18] Eastern Virginia Med Sch, Dept Otolaryngol Head & Neck Surg, Norfolk, VA 23501 USA

[19] Guys & St Thomas NHS Fdn Trust, London, England

[20] Univ Hosp Nancy, ENT Dept, Brabois ILM, Nancy, France

[21] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium

[22] Opuscomms, London, England

[23] Univ Calif Los Angeles, Dept Head & Neck Surg, Rhinol & Endoscop Skull Base Surg, Los Angeles, CA USA

[24] Univ Pittsburgh, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Sinonasal Disorders & Allergy, Pittsburgh, PA 15261 USA

[25] Dept Microbiol Immunol & Transplantat, Allergy & Clin Immunol Res Grp, Leuven, Belgium

[26] Univ North Carolina Chapel Hill, Div Rhinol Allergy & Endoscop Skull Base Surg, Chapel Hill, NC USA

[27] Univ Hosp Leuven, Dept Otorhinolaryngol Head & Neck Surg, Leuven, Belgium

来源：

ALLERGY | 2019年 / 74卷 / 12期

关键词：

asthma; biologics; chronic rhinosinusitis; nasal polyps; type; 2; inflammation; ENDOSCOPIC SINUS SURGERY; ADULT CHRONIC RHINOSINUSITIS; NATIONAL COMPARATIVE AUDIT; QUALITY-OF-LIFE; NASAL POLYPOSIS; OMALIZUMAB; PREVALENCE; MANAGEMENT; ALLERGY; CORTICOSTEROIDS;

D O I：

10.1111/all.13875

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4R alpha, anti-IL5, and anti-IL5R alpha have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.

引用

页码：2312 / 2319

页数：8

共 77 条

[11] Olfactory Disorders and Quality of Life-An Updated Review
Croy, Ilona
Nordin, Steven
Hummel, Thomas
[J]. CHEMICAL SENSES, 2014, 39 (03) : 185 - 194
[12] Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria
Cugno, Massimo
Asero, Riccardo
Ferrucci, Silvia
Lorini, Maurizio
Carbonelli, Vincenzo
Tedeschi, Alberto
Marzano, Angelo V.
[J]. ALLERGY, 2018, 73 (12) : 2408 - 2411
[13] Endotype-driven treatment in chronic upper airway diseases
De Greve, Glynnis
Hellings, Peter W.
Fokkens, Wytske J.
Pugin, Benoit
Steelant, Brecht
Seys, Sven F.
[J]. CLINICAL AND TRANSLATIONAL ALLERGY, 2017, 7
[14] Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology
de Loos, Dirk Dietz
Lourijsen, Evelijn S.
Wildeman, Maarten A. M.
Freling, Nicole J. M.
Wolvers, Marije D. J.
Reitsma, Sietze
Fokkens, Wytske J.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (03) : 1207 - 1214
[15] Prevalence of Polyp Recurrence After Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyposis
DeConde, Adam S.
Mace, Jess C.
Levy, Joshua M.
Rudmik, Luke
Alt, Jeremiah A.
Smith, Timothy L.
[J]. LARYNGOSCOPE, 2017, 127 (03) : 550 - 555
[16] Diamant Z, 2019, ALLERGY
[17] Much ado about Biologicals: Highlights of the Master Class on Biologicals, Prague, 2018
Diamant, Zuzana
Vijverberg, Susanne J.
Agache, Ioana
Bjermer, Leif
Chaker, Adam
Gevaert, Philippe
Hellings, Peter W.
Nair, Parameswaran
O'Mahony, Liam
Panzner, Petr
Pohunek, Petr
Vasakova, Martina
[J]. ALLERGY, 2019, 74 (04) : 837 - 840
[18] Influence of asthma on quality of life and clinical characteristics of patients with nasal polyposis
Dudvarski, Zoran
Djukic, Vojko
Janosevic, Ljiljana
Tomanovic, Nada
Soldatovic, Ivan
[J]. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2013, 270 (04) : 1379 - 1383
[19] The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change
Ertas, R.
Ozyurt, K.
Atasoy, M.
Hawro, T.
Maurer, M.
[J]. ALLERGY, 2018, 73 (03) : 705 - 712
[20] Anti-IL5 therapies for asthma
Farne, Hugo A.
Wilson, Amanda
Powell, Colin
Bax, Lynne
Milan, Stephen J.
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (09):

← 1 2 3 4 5 6 7 8 →